🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareGLP-1 and dental health — dry mouth, TMJ, and oral microbiome

GLP-1 and dental health — dry mouth, TMJ, and oral microbiome

Dr.GastroMayo Sat, Feb 28, 2026 at 2:15 PM 12 replies 846 viewsPage 1 of 3
Dr.GastroMayo
VIP Member
2,345
13,456
Jan 2024
Mayo Clinic, MN
Feb 28, 2026 at 2:15 PM#1

I keep finding that the number in the press summary and the number in the paper are not the same number, and the difference is always in the same direction.

What I am trying to establish is how to read a result like this without either dismissing it or over-reading it, since the summaries all read like press releases.

Practical detail welcome, however dull — the duller the better.

45 15mike_nyc, VendorMark, COA_Karl and 42 others
Reply Quote Save Share Report
Dr.RenalNash
VIP Member
1,234
7,890
Mar 2024
Nashville, TN
Feb 28, 2026 at 2:25 PM#2

Taking the question as asked, rather than the general version of it. Relative and absolute effects need reading together. A 20% relative reduction on a high baseline risk is a large absolute benefit; the same relative figure on a low baseline risk is a small one, and press summaries almost always quote the relative number because it is bigger.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

Last edited: Feb 28, 2026 at 7:25 PM
44 14pam_stl, wei_SG, cory_ATX and 41 others
Reply Quote Save Share Report
Dr.LipidDallas
VIP Member
2,678
14,567
Dec 2023
Dallas, TX
Feb 28, 2026 at 2:35 PM#3
Dr.RenalNash said:
Relative and absolute effects need reading together.
Dr.RenalNash said:
...regarding the trial evidence...

I think this is an underappreciated point. To expand on it with some data:

A recent meta-analysis of 12 RCTs (n=8,400) found that the trial evidence was associated with a significant effect size across diverse patient populations[1].

The NNT was 8, which is comparable to antihypertensives for stroke reduction. That's a strong clinical argument for this approach.

43 13cory_ATX, lori_vegas, Dr.PulmRoch and 40 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
nick_newbie
New Member
18
56
Jun 2026
Virginia
Online
Feb 28, 2026 at 2:45 PM#4
Dr.GastroMayo said:
I keep finding that the number in the press summary and the number in the paper are not the same number, and the difference is always in the same…

This matches mine closely enough to be worth saying so. The gap between trial results and real-world results is consistent and it is not fraud. Trial participants get titration by protocol, scheduled contact, free drug and dietetic support; removing that infrastructure costs a few percentage points every time it has been measured. When your own curve sits below the published mean, that is the likeliest explanation before anything about you or your material.

42 12LarryQC_SD, wanda_boise, NurseAsh_DET and 39 others
Reply Quote Save Share Report
james_edin
Member
289
1,234
Sep 2024
Edinburgh, UK
Feb 28, 2026 at 3:36 PM#5

Adding the clinical framing, because it changes how the question reads.

Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals. Bayesian approaches provide probability distributions that are more intuitive for clinical decision-making.

For example: "There is a 98.5% probability that semaglutide 2.4mg produces >10% weight loss vs placebo" is more actionable than "RR 3.4, 95% CI 2.8-4.1, p<0.001."

The the trial evidence evidence is strong under both frameworks, but Bayesian analysis better communicates the degree of certainty for individual patient counseling.

41 11bbq_ray_KC, oliver_london, tane_welly and 38 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register